Three new truncation mutants have been discovered in primary human tumors and cell lines. These mutants may possess oncogenic activities and render some tumors resistant to certain inhibitors. These newly discovered mutants may be used as biomarkers for predicting patients? response to specific targeting agents.
Researchers at Stony Brook University discovered three new truncation mutants of EGFR in primary human tumors and cell lines. These mutations may be used as biomarkers for predicting a patients? response to anti-EGFR drugs, molecular diagnostic for micrometastasis/minimal residual disease monitoring or become new therapeutic targets for drug and antibody development.
New EGFR truncation mutants may be used for predicting patients? response to EGFR targeting agents. - Could become new therapeutic targets for drug and antibody development.
Biomarker for predicting patients? response to anti-EGFR drugs. - Therapeutic target for drug and antibody development.
Edward Chan, Assistant Professor, Pediatrics
James Keller, Research Assistant, Molecular Genetics and Microbiology
Development partner - Commercial partner - Licensing
Available for license. The team seeks to develop and commercialize, by an exclusive or non-exclusive license agreement and/or sponsored research, with a company active in the area.
Sean Boykevisch, Director, Intellectual Property Partners, email@example.com, 6316326952
Antibody developed; need clinical validation. PCT Publication No. WO 2011-140391